Free tool
FAERS Monitor: Betoptic
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019270 or its brand name (Betoptic, Betaxolol Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
325
Serious
301
93% of reports
Hospitalization
219
Death reported
37
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fall58
- dyspnoea47
- drug ineffective37
- asthma33
- nausea32
- pain31
- limb injury30
- wound30
- cardiac failure congestive29
- fatigue29
- haemorrhage29
- transient ischaemic attack29
- diarrhoea28
- dizziness28
- vomiting26
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 8 |
| 2006 | 5 |
| 2007 | 6 |
| 2008 | 4 |
| 2009 | 6 |
| 2010 | 6 |
| 2011 | 6 |
| 2012 | 7 |
| 2013 | 3 |
| 2014 | 5 |
| 2015 | 6 |
| 2016 | 10 |
| 2017 | 14 |
| 2018 | 31 |
| 2019 | 45 |
| 2020 | 19 |
| 2021 | 11 |
| 2022 | 33 |
| 2023 | 27 |
| 2024 | 33 |
| 2025 | 22 |
| 2026 | 16 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,834 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| limb injurySignal | 30 | 71.6 | 50.9 | 2,017 |
| woundSignal | 30 | 69.5 | 49.4 | 1,959 |
| transient ischaemic attackSignal | 29 | 55.7 | 39.3 | 1,504 |
| cardiac failure congestiveSignal | 29 | 23.4 | 16.5 | 601 |
| asthmaSignal | 33 | 18.9 | 13.7 | 545 |
| haemorrhageSignal | 29 | 18.0 | 12.7 | 450 |
| fallSignal | 58 | 11.3 | 8.9 | 542 |
| dyspnoeaSignal | 47 | 5.4 | 4.1 | 167 |
| dizzinessSignal | 28 | 3.6 | 2.5 | 52 |
| vomitingSignal | 26 | 3.6 | 2.5 | 47 |
| painSignal | 31 | 3.3 | 2.3 | 48 |
| diarrhoeaSignal | 28 | 2.8 | 2.0 | 32 |
| nauseaSignal | 32 | 2.6 | 1.9 | 32 |
| fatigueSignal | 29 | 2.4 | 1.7 | 23 |
| drug ineffective | 37 | 1.8 | 1.3 | 14 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.